US biosimilars bill adopts Hatch/Waxman exclusivity model
This article was originally published in Scrip
Executive Summary
US Democratic congressman Henry Waxman's latest biosimilars proposal would give innovators five years of marketing protection for novel biologicals and three years of exclusivity for modified formulations of previously approved products.